The Bellvitge Biomedical Research Institute (IDIBELL) was founded in 2004 and conducts both basic and clinical research with the aim of improving people’s quality of life.
Located in Hospitalet de Llobregat, to the south of Barcelona, its research activity focusses on cancer, neuroscience, translational medicine and regenerative medicine.
It is a Generalitat de Catalunya CERCA centre and was one of the first five Spanish research centres to receive accreditation from the Carlos III Health Institute. In 2015, the European Commission also presented IDIBELL with the “HR Excellence in Research” award, identifying the institute as a provider and advocate of a stimulating research working environment.
In addition, in 2020 it integrated the Center of Regenerative Medicine in Barcelona (CMR[B]) and is now the headquarters of the Program for Clinical Translation of Regenerative Medicine of Catalonia (P-CMR[C]).
